ホームページ GPCR & G Protein GLP-1 Receptor

GLP-1 Receptor

GLP-1 Receptor製品

  • All (6)
  • GLP-1 Receptor作動薬(3)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
Cell Rep Med, 2025, 6(6):102156
Cancers (Basel), 2025, 17(4)598
J Immunother Cancer, 2024, 12(3)e008431
E1827 ECC5004(AZD5004) ECC5004(AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 receptor agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
Cell Rep Med, 2025, 6(6):102156
Cancers (Basel), 2025, 17(4)598
J Immunother Cancer, 2024, 12(3)e008431
E1827 ECC5004(AZD5004) ECC5004(AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 receptor agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
S8256 Liraglutide Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
Cell Rep Med, 2025, 6(6):102156
Cancers (Basel), 2025, 17(4)598
J Immunother Cancer, 2024, 12(3)e008431
E1827 ECC5004(AZD5004) ECC5004(AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 receptor agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease.
S9851 Danuglipron (PF-06882961) Danuglipron (PF-06882961), a non-peptide agonist, activates the canonical G protein signaling activity only in the Glucagon-like peptide-1 (GLP-1) receptor with Trp33ECD.
united states